Alteration of cell-cycle regulation in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 18, Issue 6, 2008, Pages 1169-1182

  Nam, E J ^a   Kim, Y T ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cell cycle regulation; Cyclin; Cyclin dependent kinase; Cyclin dependent kinase inhibitor; Ovarian cancer

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; P21 ACTIVATED KINASE; PROTEIN MDM2; PROTEIN P14; PROTEIN P16; PROTEIN P27; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; HUMAN; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; OVARY CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

CELL CYCLE; CYCLINS; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FEMALE; HUMANS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 55949105520     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2008.01191.x     Document Type: Article

References (137)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004 54 : 8 29.
2. Brewer MA, Johnson K, Follen M et al. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 2003 9 : 20 30.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70.
4. Milde-Langosch K, Riethdorf S. Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol 2003 196 : 224 44.
5. Hashiguchi Y, Tsuda H, Inoue T et al. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 2004 35 : 165 75.
6. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004 164 : 1511 8.
7. Nicosia SV, Bai W, Cheng JQ et al. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 2003 17 : 927 43.
8. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005 24 : 2796 809.
9. Todd MC, Sclafani RA, Langan TA. Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein. Oncogene 2000 19 : 258 64.
10. Xing EP, Nie Y, Song Y et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999 5 : 2704 13.
11. O'Neill CJ, McBride HA, Connolly LE et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007 50 : 773 9.
12. Khouja MH, Baekelandt M, Nesland JM, Holm R. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 2007 26 : 418 25.
13. Kommoss S, du Bois A, Ridder R et al. Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 2007 96 : 306 13.
14. Bali A, O'Brien PM, Edwards LS et al. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004 10 : 5168 77.
15. Milde-Langosch K, Hagen M, Bamberger AM, Loning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 2003 22 : 168 74.
16. Hashiguchi Y, Tsuda H, Yamamoto K et al. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 2001 32 : 988 96.
17. Sui L, Dong Y, Ohno M et al. Inverse expression of Cdk4 and p16 in epithelial ovarian tumors. Gynecol Oncol 2000 79 : 230 7.
18. Kusume T, Tsuda H, Kawabata M et al. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999 5 : 4152 7.
19. Dong Y, Walsh MD, McGuckin MA et al. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997 74 : 57 63.
20. Armes JE, Lourie R, de Silva M et al. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 2005 24 : 363 8.
21. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res 1997 237 : 7 13.
22. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989 243 : 934 7.
23. Marchini S, Codegoni AM, Bonazzi C et al. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer 1997 76 : 146 9.
24. Campbell IG, Foulkes WD, Beynon G et al. LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer 1995 63 : 222 5.
25. Ichikawa Y, Yoshida S, Koyama Y et al. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 1996 69 : 466 70.
26. Kudoh K, Ichikawa Y, Yoshida S et al. Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer 2002 99 : 579 82.
27. Foster SA, Wong DJ, Barrett MT, Galloway DA. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998 18 : 1793 801.
28. Suh SI, Cho JW, Baek WK et al. Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. Cancer Lett 2000 153 : 175 82.
29. Katsaros D, Cho W, Singal R et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 2004 94 : 685 92.
30. Shih YC, Kerr J, Liu J et al. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours. Int J Cancer 1997 70 : 508 11.
31. Niederacher D, Yan HY, An HX et al. CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br J Cancer 1999 80 : 1920 6.
32. Ryan A, Al-Jehani RM, Mulligan KT, Jacobs IJ. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis. Gynecol Oncol 1998 68 : 14 7.
33. Vang R, Gown AM, Farinola M et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol 2007 31 : 653 63.
34. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998 51 : 1 7.
35. Dhar KK, Branigan K, Parkes J et al. Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer 1999 81 : 1174 81.
36. Worsley SD, Ponder BA, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997 64 : 189 95.
37. Barbieri F, Cagnoli M, Ragni N et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 1999 5 : 1837 42.
38. Masciullo V, Scambia G, Marone M et al. Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer 1997 74 : 390 5.
39. Dimova I, Zaharieva B, Raicheva S et al. Association of CyclinD1 copy number changes with histological type in ovarian tumors. Acta Oncol 2004 43 : 675 9.
40. Diebold J, Mosinger K, Peiro G et al. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. J Pathol 2000 190 : 564 71.
41. Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer 1998 22 : 66 71.
42. Barbieri F, Lorenzi P, Ragni N et al. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology 2004 66 : 310 5.
43. Matsumoto M, Furihata M, Ishikawa T et al. Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma. Br J Cancer 1999 80 : 256 61.
44. Volm M, Koomagi R, Stammler G et al. Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia. Int J Cancer 1997 74 : 508 12.
45. Dodson MK, Cliby WA, Xu HJ et al. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res 1994 54 : 610 3.
46. Liu Y, Heyman M, Wang Y et al. Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. Int J Cancer 1994 58 : 663 7.
47. Kim TM, Benedict WF, Xu HJ et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res 1994 54 : 605 9.
48. Konstantinidou AE, Korkolopoulou P, Vassilopoulos I et al. Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. Gynecol Oncol 2003 88 : 369 78.
49. Havrilesky LJ, Alvarez AA, Whitaker RS et al. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol 2001 83 : 491 500.
50. Fang X, Jin X, Xu HJ et al. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 1998 16 : 1 8.
51. Dong Y, Walsh MD, McGuckin MA et al. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 1997 74 : 407 15.
52. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999 13 : 1501 12.
53. el-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993 75 : 817 25.
54. Psyrri A, Bamias A, Yu Z et al. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 2005 11 : 8384 90.
55. Plisiecka-Halasa J, Karpinska G, Szymanska T et al. P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 2003 14 : 1078 85.
56. Rose SL, Goodheart MJ, DeYoung BR et al. p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res 2003 9 : 1028 32.
57. Geisler HE, Geisler JP, Miller GA et al. p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer 2001 92 : 781 6.
58. Sui L, Dong Y, Ohno M et al. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001 83 : 56 63.
59. Anttila MA, Kosma VM, Hongxiu J et al. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 1999 79 : 1870 8.
60. Masciullo V, Sgambato A, Pacilio C et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999 59 : 3790 4.
61. Baekelandt M, Holm R, Trope CG et al. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res 1999 5 : 2848 53.
62. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002 8 : 1323 7.
63. Geisler JP, Geisler HE. Tumor markers and molecular biological markers in gynecologic malignancies. Curr Opin Obstet Gynecol 2001 13 : 31 9.
64. Saegusa M, Machida BD, Okayasu I. Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer 2001 92 : 1177 89.
65. Elbendary AA, Cirisano FD, Evans AC Jr. et al. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 1996 2 : 1571 5.
66. LaBaer J, Garrett MD, Stevenson LF et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997 11 : 847 62.
67. Blain SW, Scher HI, Cordon-Cardo C, Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003 3 : 111 5.
68. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995 269 : 682 5.
69. Kawamata N, Morosetti R, Miller CW et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995 55 : 2266 9.
70. Shigemasa K, Shiroyama Y, Sawasaki T et al. Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. Int J Oncol 2001 18 : 953 8.
71. Korkolopoulou P, Vassilopoulos I, Konstantinidou AE et al. The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 2002 85 : 404 14.
72. Schmider-Ross A, Pirsig O, Gottschalk E et al. Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. J Cancer Res Clin Oncol 2006 132 : 163 70.
73. Newcomb EW, Sosnow M, Demopoulos RI et al. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 1999 154 : 119 25.
74. Farley J, Smith LM, Darcy KM et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 2003 63 : 1235 41.
75. Sui L, Tokuda M, Ohno M et al. The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol 1999 73 : 202 9.
76. Courjal F, Louason G, Speiser P et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996 69 : 247 53.
77. Marone M, Scambia G, Giannitelli C et al. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer 1998 75 : 34 9.
78. Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A et al. Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol 2001 32 : 808 13.
79. Tsuda H, Bandera CA, Birrer MJ et al. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 2004 67 : 291 9.
80. Rosen DG, Yang G, Deavers MT et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006 106 : 1925 32.
81. Hayami R, Sato K, Wu W et al. Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Cancer Res 2005 65 : 6 10.
82. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001 264 : 56 66.
83. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997 88 : 323 31.
84. Weber JD, Kuo ML, Bothner B et al. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 2000 20 : 2517 28.
85. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003 97 : 389 404.
86. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003 21 : 285 91.
87. Klemi PJ, Pylkkanen L, Kiilholma P et al. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995 76 : 1201 8.
88. Shelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer 1995 72 : 521 7.
89. Chan WY, Cheung KK, Schorge JO et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000 156 : 409 17.
90. Anttila MA, Ji H, Juhola MT et al. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol 1999 18 : 42 51.
91. Skilling JS, Sood A, Niemann T et al. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996 13 : 117 23.
92. Greenblatt MS, Chappuis PO, Bond JP et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001 61 : 4092 7.
93. Crook T, Brooks LA, Crossland S et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998 17 : 1681 9.
94. Lassus H, Leminen A, Lundin J et al. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003 91 : 504 12.
95. Baekelandt M, Kristensen GB, Nesland JM et al. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol 1999 17 : 2061.
96. Levesque MA, Katsaros D, Massobrio M et al. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clin Cancer Res 2000 6 : 3260 70.
97. de Graeff P, Hall J, Crijns AP et al. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer 2006 95 : 627 33.
98. Fallows S, Price J, Atkinson RJ et al. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001 194 : 68 75.
99. Lavarino C, Pilotti S, Oggionni M et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000 18 : 3936 45.
100. Reles A, Wen WH, Schmider A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001 7 : 2984 97.
101. Dogan E, Saygili U, Tuna B et al. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 2005 97 : 46 52.
102. Skomedal H, Kristensen GB, Abeler VM et al. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol 1997 181 : 158 65.
103. Harlozinska A, Bar J, Montenarh M. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas. Anticancer Res 2000 20 : 1049 56.
104. Tanner B, Hengstler JG, Laubscher S et al. mdm 2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 1997 74 : 438 42.
105. Palazzo JP, Monzon F, Burke M et al. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Hum Pathol 2000 31 : 698 704.
106. Foulkes WD, Stamp GW, Afzal S et al. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer 1995 72 : 883 8.
107. Mi RR, Ni H. MDM2 sensitizes a human ovarian cancer cell line. Gynecol Oncol 2003 90 : 238 44.
108. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995 83 : 993 1000.
109. Weber JD, Taylor LJ, Roussel MF et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999 1 : 20 6.
110. Stott FJ, Bates S, James MC et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998 17 : 5001 14.
111. Esteller M, Cordon-Cardo C, Corn PG et al. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001 61 : 2816 21.
112. Canman CE, Lim DS, Cimprich KA et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998 281 : 1677 9.
113. Sorensen CS, Syljuasen RG, Falck J et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003 3 : 247 58.
114. Chen Z, Xiao Z, Chen J et al. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2003 2 : 543 8.
115. Bulavin DV, Higashimoto Y, Demidenko ZN et al. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 2003 5 : 545 51.
116. Gatti RA, Berkel I, Boder E et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988 336 : 577 80.
117. Barboule N, Baldin V, Jozan S et al. Increased level of p21 in human ovarian tumors is associated with increased expression of cdk2, cyclin A and PCNA. Int J Cancer 1998 76 : 891 6.
118. Gatei M, Sloper K, Sorensen C et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 2003 278 : 14806 11.
119. Yarden RI, Pardo-Reoyo S, Sgagias M et al. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002 30 : 285 9.
120. Koike M, Takeuchi S, Park S et al. Ovarian cancer: loss of heterozygosity frequently occurs in the ATM gene, but structural alterations do not occur in this gene. Oncology 1999 56 : 160 3.
121. Thorstenson YR, Roxas A, Kroiss R et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003 63 : 3325 33.
122. Foulkes WD, Campbell IG, Stamp GW, Trowsdale J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer 1993 67 : 268 73.
123. Gabra H, Watson JE, Taylor KJ et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996 56 : 950 4.
124. Falck J, Mailand N, Syljuasen RG et al. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001 410 : 842 7.
125. Zhang P, Gao W, Li H et al. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. Biochem Biophys Res Commun 2005 328 : 567 72.
126. Miller CW, Ikezoe T, Krug U et al. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 2002 33 : 17 21.
127. Karlsson C, Katich S, Hagting A et al. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol 1999 146 : 573 84.
128. Broggini M, Buraggi G, Brenna A et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res 2000 20 : 4835 40.
129. Hu W, Wu W, Nash MA et al. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines. Anticancer Res 2000 20 : 729 33.
130. Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005 32 : 169 76.
131. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006 439 : 353 7.
132. Dressman HK, Berchuck A, Chan G et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007 25 : 517 25.
133. Fey MF. Genomics and proteomics: expression arrays in clinical oncology. Ann Oncol 2004 15 (Suppl. 4 iv163 5.
134. Fehrmann RS, Li XY, van der Zee AG et al. Profiling studies in ovarian cancer: a review. Oncologist 2007 12 : 960 6.
135. Zhu Y, Wu R, Sangha N et al. Classifications of ovarian cancer tissues by proteomic patterns. Proteomics 2006 6 : 5846 56.
136. Skilling JS, Powills K, Lager DJ et al. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: lack of correlation with familial and clinical factors. Gynecol Oncol 1996 61 : 180 8.
137. Shimizu M, Nikaido T, Toki T et al. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999 85 : 669 77.